Development of RP-HPLC Method for Estimation of Valsartan and Hydrochlorothiazide in Tablets



  • Cylma Menezes
  • Vishal M
  • Shyamkumar B
  • Reema N


A simple, efficient and reproducible reversed phase high performance liquid chromatographic (RP-HPLC) method was developed and validated for the simultaneous estimation of valsartan and hydrochlorothiazide in bulk and in tablets. A column having 250 x 4.6 mm i.d. (Kromasil C18) in isocratic mode with mobile phase containing 50 mM potassium dihydrogen o-phosphate buffer (triethylamine 0.2%), (pH 3.7 adjusted with o-phosphoric acid): acetonitrile (56:44 v/v) was used. The flow rate was 1.0 ml/min and effluent was monitored at 232 nm.  The retention time of valsartan and hydrochlorothiazide was 10.15 and 3.78 min respectively. All calibration curves showed good linear correlation coefficients within the tested limits (r2 > 0.9995). The linearity dynamic range was found to be 20-150 µg/ml and 5-45 µg/ml for valsartan and hydrochlorothiazide respectively. Percentage recoveries for valsartan and Hydrochlorothiazide were 100.45 % and 98.75 % respectively. All the analytical validation parameters were determined and found in the limit as per the International Conference on Harmonization (ICH) guidelines which indicates the validity of the method. The developed method was found to be accurate, precise and robust for the simultaneous estimation of valsartan and hydrochlorothiazide in bulk and in tablets.


Download data is not yet available.


Metrics Loading ...


Hydroclorothiazide, RP-HPLC, Quantitative Estimation, Valsartan, Method Validation




How to Cite

Menezes C, M V, B S, N R. Development of RP-HPLC Method for Estimation of Valsartan and Hydrochlorothiazide in Tablets. Scopus Indexed [Internet]. 2013 Dec. 31 [cited 2024 May 18];6(4):2240-4. Available from:



Research Articles


Chaudhary BA, Patel KK, Chaudhary S, Gadhvil KV (2010).Estimation of valsartan and hydrochlorothiazide in pharmaceutical dosage forms by absorption ratio method. Int J A Bio Pharmaceut Techn 1: 455.

Gupta KR, Wadodkar AR, Wadodkar SD (2010). UV spectrophotometric methods for estimation of valsartan in bulk and tablet dosage form. Int J Chem Tech 2: 985-9.

Raja A, Selvakumar D (2010). Method development and validation of hydrochlorothiazide in tablet dosage form by UV Spectroscopy. IJPS 1: 369-71.

Indian Pharmacopoeia (2010). 6th ed. Controller of Publication 3: 2286.

International Conference on Harmonization, (2005). Q2 (R1), Harmonised Tripartite Guidelines, Validation of analytical procedures: text and methodology, Geneva.

Satana E, Altinay S, Goger NG, Ozkan SA, Senturk Z (2001). Simultaneous determination of valsartan and hydrochlorothiazide in tablets by first-derivative ultraviolet spectrophotometry and LC. J Pharm Biomed Anal 25:1009-13.

Hillaert S, Bossche W (2003). Simultaneous determination of hydrochlorothiazide and several angiotensin-II-receptor antagonists by capillary electrophoresis. J Pharm Biomed Anal 31: 329-39.

Ramadan NK, Mohamed HM, Moustafa AA (2010). Rapid and highly sensitive HPLC and TLC methods for Quantitation of Amlodipine Besilate and Valsartan in bulk powder and in pharmaceutical dosage forms and in human plasma. Anal Lett 43: 570-81.

Wankhede SB, Raka KC, Wadkar SB, Chitlange SS (2010). Spectrophotometric and HPLC methods for simultaneous estimation of amlodipine besilate, losartan potassium and hydrochlorothiazide in tablets. IJPS 72:136-40.

Liu F, Xu F, Gao X, Zhang J, Guo Q (2007). Determination of hydrochlorothiazide in human plasma by liquid chromatography- mass spectroscopy. J Pharm Biomed Anal 44:1187–91.

Macek J, Klima J, Ptacek P (2006). Rapid determination of valsartan in human plasma by protein precipitation and high-performance liquid chromatography. J Chromatogr B Analyt Technol Biomed Life Sci 832:169-72.

Krishnaiaha BC, Reddy AR, Kumar R, Mukkanti K (2010). Stability-indicating UPLC method for determination of Valsartan and their degradation products in active pharmaceutical ingredient and pharmaceutical dosage forms. J Pharm Biomed Anal 53:483-9.

The United State Pharmacopoeia/The National Formulary (1990), USP XXII/NF XVII, United State Pharmacopeial Convention, Inc 3: 496-498.